Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$1.46 USD

1.46
165,357

+0.03 (2.10%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.47 +0.01 (0.68%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Spero Therapeutics, Inc. (SPRO) Loses -9.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 2.94% and 70.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Urogen Pharma (URGN) delivered earnings and revenue surprises of 7.38% and 20.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 12.16% and 34.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of -50% and 7.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

by Zacks Equity Research

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & More

by Zacks Equity Research

Regulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week.

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

by Zacks Equity Research

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

Spero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 1.14% and 13.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Spero Therapeutics, Inc. (SPRO) Q1 Earnings Expected to Decline

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Spero Therapeutics (SPRO) This Earnings Season?

by Zacks Equity Research

Spero Therapeutics (SPRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What to Expect Ahead of BlackBerry's (BB) Q4 Earnings Release

by Zacks Equity Research

BlackBerry's (BB) revenues in fourth-quarter fiscal 2022 are likely to have benefited from its investments in product development and go-to-market strategy.

Spero (SPRO) Application for UTI Drug Gets Priority Review

by Zacks Equity Research

Spero's (SPRO) NDA for tebipenem HBr oral tablets for complicated urinary tract infections gets Priority Review.

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 0.00% and 2.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study

by Zacks Equity Research

Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.

Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

by Zacks Equity Research

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.